Skyhawk Therapeutics, Inc. announced the signing of an exclusive worldwide collaboration agreement with Sanofi to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets.
[Skyhawk Therapeutics, Inc.]